BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27

• Press Releases

  RIVANNA selected for prestigious MedTech Innovator 2025 Accelerator Cohort

  June 12, 2025

   · 

  3 min read
• Press Releases

  U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

  June 12, 2025

   · 

  10 min read
• Press Releases

  Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon’s Board of Directors

  June 12, 2025

   · 

  2 min read
• Press Releases

  Model Medicines Selected for BARDA VANGUARD Program, Strengthening U.S. National Defense Against Biological Threats

  Program designed to accelerate Model Medicines’ deployment of AI-generated medical countermeasures that enhance the U.S.’ readiness for public health emergencies.

  June 12, 2025

   · 

  1 min read
• Press Releases

  Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

  June 12, 2025

   · 

  7 min read
• Press Releases

  Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

  June 12, 2025

   · 

  3 min read
• Press Releases

  Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

  June 12, 2025

   · 

  21 min read
• Press Releases

  Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

  June 12, 2025

   · 

  3 min read
• Press Releases

  Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison

  June 12, 2025

   · 

  16 min read
• Press Releases

  Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

  June 12, 2025

   · 

  16 min read